TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29103962

Group type: EXPERIMENTAL
Intervention: Decellularized human corneal stromal lamina alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Decellularized human corneal stromal lamina with autologous adipose‐derived adult stem cell recellularization
Number of subjects: 9
Study: 26963689

Group type: EXPERIMENTAL
Intervention: Aripiprazole (started at 2 mg daily, titrated to a maximum of 15 mg daily)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo (started at 2 mg daily, titrated to a maximum of 15 mg daily)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Aripiprazole (among participants with Trail Making Test scaled score of 7 or higher)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo (among participants with Trail Making Test scaled score of 7 or higher)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Aripiprazole and Placebo (among participants with Trail Making Test scaled score of less than 7)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Aripiprazole and Placebo
Number of subjects: 181
Study: 25440887

Group type: EXPERIMENTAL
Intervention: BP-SES
Number of subjects: 2737

Group type: COMPARATOR
Intervention: DP-SES
Number of subjects: 2737
Study: 22831805

Group type: EXPERIMENTAL
Intervention: Contact lenses
Number of subjects: 57

Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 57
Study: 20386995

Group type: EXPERIMENTAL
Intervention: Double-blind cyclical alternative medications for osteoarthritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-blind cyclical alternative medications for chronic neuropathic pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-blind cyclical alternative medications for ADHD
Number of subjects: 0
Study: 18469572

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 800 microg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 400 microg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 200 microg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (all doses)
Number of subjects: 8
Study: 18320340

Group type: EXPERIMENTAL
Intervention: Short-term desmopressin (0.2 mg for first 3 weeks, 0.4 mg for following 3 weeks) plus 12 weeks of enuretic alarm therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Enuretic alarm therapy alone for 12 weeks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Short-term desmopressin plus alarm therapy
Number of subjects: 58
Study: 15029120

Group type: EXPERIMENTAL
Intervention: Antibacterial drug treatment with sumamed
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Antibacterial drug treatment with rulid
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Antibacterial drug treatment with clindamycin
Number of subjects: 245
Study: 11391325

Group type: EXPERIMENTAL
Intervention: Viral RT-PCR positive for picornavirus and parainfluenza
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Viral RT-PCR positive
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Children born during winter and summer months
Number of subjects: 495
Study: 9430184

Group type: EXPERIMENTAL
Intervention: Pamidronate (Aredia)
Number of subjects: 0
Study: 8305102

Group type: EXPERIMENTAL
Intervention: Arthroscope-guided surgery
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 73
Study: 3520383

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31682461

Group type: EXPERIMENTAL
Intervention: Enriched-polyunsaturated fat hypocaloric diet (diet P)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Enriched-monounsaturated fat hypocaloric diet (diet M)
Number of subjects: 360
Study: 28000174

Group type: EXPERIMENTAL
Intervention: ORS + Gelatin Tannate
Number of subjects: 60

Group type: COMPARATOR
Intervention: ORS
Number of subjects: 60
Study: 25015782

Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 352

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 352
Study: 24734423

Group type: EXPERIMENTAL
Intervention: 1 ml of liquid probiotic Enterococcus faecium L3 (5x10(8) CFU/ml) 2 times a day for 10 days (mature infants)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 1 ml of liquid probiotic Enterococcus faecium L3 (5x10(8) CFU/ml) 2 times a day for 10 days (premature infants)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard therapy (mature infants)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard therapy (premature infants)
Number of subjects: 94
Study: 21788265

Group type: EXPERIMENTAL
Intervention: Long-term practice group (60 hours of rehabilitation over 16 months with bilateral arm movements and active neuromuscular stimulation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Short-term practice group (1 treatment protocol over 4 weeks)
Number of subjects: 18
Study: 19326288

Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg prolonged-release preparation, CircadinTM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramelteon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0
Study: 16769957

Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (3,4-DAP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15619134

Group type: EXPERIMENTAL
Intervention: Methylene blue (130 mg twice daily for 3 days)
Number of subjects: 24
Study: 11703885

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg bid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg extended-release daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tolterodine (various doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oxybutynin 5 mg tid
Number of subjects: 10
Study: 9219047

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diltiazem and dextroamphetamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 10
Study: 8484548

Group type: EXPERIMENTAL
Intervention: Propofol induction followed by desflurane and nitrous oxide (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol induction followed by propofol infusion and nitrous oxide (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Desflurane and nitrous oxide induction and maintenance (Group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Desflurane induction and maintenance (Group 4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intermediate recovery in Group 4
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Psychomotor function test results
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative narcotic requirement
Number of subjects: 60
Study: 3547179

Group type: EXPERIMENTAL
Intervention: Diacereine (100 mg/die for 4 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Diacereine (100 mg/die for 2 weeks)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Diacereine (100 mg/die 5 days a week for 12 weeks)
Number of subjects: 71
Study: 30047584

Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fed state
Number of subjects: 16
Study: 27531238

Group type: EXPERIMENTAL
Intervention: Hybrid of intracavitary and interstitial brachytherapy (HBT) with 30‐30.6 Gy in 15‐17 fractions of whole pelvic radiotherapy concurrent with weekly CDDP (40 mg/m(2)), followed by 24 Gy in 4 fractions of HBT and central shield EBRT up to 50‐50.4 Gy in 25‐28 fractions.
Number of subjects: 55

Group type: COMPARATOR
Intervention: HBT
Number of subjects: 55
Study: 24749664

Group type: EXPERIMENTAL
Intervention: Five-week online intervention for hearing-aid users
Number of subjects: 76

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 76
Study: 22898744

Group type: EXPERIMENTAL
Intervention: Immediate extinction of non-masked conditioned stimuli (CS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed extinction
Number of subjects: 0
Study: 20459918

Group type: EXPERIMENTAL
Intervention: Water‐pipe smoking
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 30
Study: 18655753

Group type: EXPERIMENTAL
Intervention: Xylometazoline 0.1% (n = 29)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (saline solution; n = 32)
Number of subjects: 61
Study: 16428155

Group type: EXPERIMENTAL
Intervention: Butenafine once daily for 2 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clotrimazole twice daily for 4 weeks
Number of subjects: 80
Study: 12114432

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 100 mg/m2 on day 1 plus Gemcitabine (Gem) 1250 mg/m2 on days 1 and 8 every 3 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) plus Gemcitabine (Gem)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High ERCC1 mRNA levels
Number of subjects: 56
Study: 10459515

Group type: EXPERIMENTAL
Intervention: Coculture with attached cumulus tissue
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Coculture with added cumulus tissue
Number of subjects: 247

Group type: COMPARATOR
Intervention: Culture without cumulus tissue
Number of subjects: 247
Study: 7850941

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (predrug)
Number of subjects: 16
Study: 2351364

Group type: EXPERIMENTAL
Intervention: Neurotropin tablets
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 385518

Group type: EXPERIMENTAL
Intervention: V. F. (peptides from bovine Factor VIII) administered at 1 mg/day in two oral doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30767422

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention consisting of in-service training, mentoring and supportive supervision, infrastructure support, and peer outreach.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (12 facilities and their catchment areas)
Number of subjects: 12
Study: 27340950

Group type: EXPERIMENTAL
Intervention: IR-Tac
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LCPT
Number of subjects: 30

Group type: COMPARATOR
Intervention: ER-Tac
Number of subjects: 30
Study: 25500935

Group type: EXPERIMENTAL
Intervention: 20 mg Cortef (glucocorticoids) administered orally in the late afternoon for 6 days
Number of subjects: 0
Study: 22890582

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (Livact group, n = 26)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional diet (Control group, n = 30)
Number of subjects: 56
Study: 21376536

Group type: COMPARATOR
Intervention: Bilateral TMJ prosthesis
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unilateral TMJ prosthesis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Normal controls
Number of subjects: 18
Study: 19446989

Group type: EXPERIMENTAL
Intervention: Stenosis >or=50% in the right leg
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Stenosis >or=50% in the left leg
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Stenosis >or=50% in both legs
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: ABI <0.9
Number of subjects: 306
Study: 17117395

Group type: EXPERIMENTAL
Intervention: memantine (titrated to 20 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 15569113

Group type: EXPERIMENTAL
Intervention: Pantoprazole (10, 20, or 40 mg daily)
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Pantoprazole (20 or 40 mg daily)
Number of subjects: 846

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846

Group type: COMPARATOR
Intervention: Nizatidine (150 mg b.d.)
Number of subjects: 846
Study: 11699749

Group type: EXPERIMENTAL
Intervention: Training with pronouns and nouns
Number of subjects: 50

Group type: COMPARATOR
Intervention: Training with full nouns only
Number of subjects: 50
Study: 9696445

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (TAPP technique)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Bassini repair
Number of subjects: 175
Study: 8002638

Group type: EXPERIMENTAL
Intervention: UFT (uracil and tegafur) 400 mg/day for 1 year
Number of subjects: 112

Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 112
Study: 2790692

Group type: EXPERIMENTAL
Intervention: CT + RT (Continuous 5-FU infusion followed by hepatic irradiation of 25.5 Gy)
Number of subjects: 37

Group type: COMPARATOR
Intervention: CT (Continuous 5-FU infusion)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patients with 4+ vascularity
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patients with Grade 1, well-differentiated histologic type
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patients with both 4+ vascularity and Grade 1 histologic type
Number of subjects: 37
Study: 801578

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.1 mg reinjection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfentanil (0.01 mg reinjection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5 mg reinjection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfentanil (0.05 mg reinjection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.1 mg reinjection) with droperidol (1.25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfentanil (0.01 mg reinjection) with droperidol (1.25 mg)
Number of subjects: 0
Study: 31376790

Group type: EXPERIMENTAL
Intervention: History of living in OHC
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Living in OHC during childhood
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: History of OHC and suicidal ideation
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Participants living in group home, foster care, and/or psychiatric facility
Number of subjects: 202
Study: 30677829

Group type: EXPERIMENTAL
Intervention: Notable Protagonists (NP)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Generic Protagonists (GP)
Number of subjects: 476
Study: 26798983

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycemic control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronologic age
Number of subjects: 0
Study: 24508337

Group type: EXPERIMENTAL
Intervention: Safety audits based on a checklist of 37 measures
Number of subjects: 50
Study: 22305777

Group type: EXPERIMENTAL
Intervention: SureFil(®) SDR™ (Dentsply, S)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calibra (Dentsply, C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post type
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post space level
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-cement interaction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Failure mode assessment
Number of subjects: 30
Study: 19926626

Group type: EXPERIMENTAL
Intervention: Event drawing (n = 69)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No event drawing (n = 56)
Number of subjects: 125
Study: 17903073

Group type: EXPERIMENTAL
Intervention: Combined continuous ethinyl estradiol (10 microg) and norethindrone acetate (1 mg) given once daily for 3 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combined continuous ethinyl estradiol and norethindrone acetate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16131023

Group type: EXPERIMENTAL
Intervention: Yogurt supplementation (125 g, 5 days a week for 9 months)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control group (no yogurt supplementation)
Number of subjects: 402
Study: 12634038

Group type: EXPERIMENTAL
Intervention: Midwives' knowledge and attitudes regarding baby walkers
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Midwives' knowledge of baby walker injury risk
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Attitude scales regarding baby walkers
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Personal experience with baby walkers
Number of subjects: 65
Study: 10716205

Group type: EXPERIMENTAL
Intervention: Facial expressions presented in the blind field to the blindsight subject (GY)
Number of subjects: 1
Study: 7489435

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5 mg/kg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (wound infiltration with bupivacaine 0.5%)
Number of subjects: 35
Study: 1942990

Group type: EXPERIMENTAL
Intervention: bemitil (0.25‐0.5 g/day orally for 5‐7 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 66
Study: 7452507

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day p.o.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Heroin self-administration
Number of subjects: 12
Study: 6520821

Group type: EXPERIMENTAL
Intervention: Intraoperative cefoxitin irrigation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Short course of intravenous cefoxitin prophylaxis and intraoperative saline irrigation
Number of subjects: 103
Study: 31187949

Group type: EXPERIMENTAL
Intervention: Acetabular diameter (AD) measurement
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Transverse acetabular diameter (TAD) measurement
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Discriminant function using both acetabular variables
Number of subjects: 200

Group type: COMPARATOR
Intervention: Inter-observer error measurement
Number of subjects: 200
Study: 29212135

Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Psychotherapy (PFPP)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 118
Study: 26721648

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 125

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 125
Study: 25253199

Group type: EXPERIMENTAL
Intervention: Initial combination therapy (iCombo)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Initial monotherapy (iMono)
Number of subjects: 508
Study: 23173697

Group type: EXPERIMENTAL
Intervention: Tradamixina (150 mg of Alga Ecklonia Bicyclis, 396 mg of Tribulus Terrestris and 144 mg of D‐Glucosamine and N‐Acetyl‐D‐Glucosamine) twice a day for 2 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Tadalafil 5 mg daily for 2 months
Number of subjects: 70
Study: 20438867

Group type: EXPERIMENTAL
Intervention: OAM (Omeprazole, Amoxicillin and Metronidazole)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Curcumin
Number of subjects: 0
Study: 17353942

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.3 mg/kg, given orally) plus a nutritionally balanced amino acid mixture
Number of subjects: 14

Group type: COMPARATOR
Intervention: acute phenylalanine/tyrosine depletion (APTD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: L-DOPA (Sinemet, 2 x 100 mg/25 mg)
Number of subjects: 14
Study: 16223394

Group type: EXPERIMENTAL
Intervention: Inferior-medial injection technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inferior-superior injection technique
Number of subjects: 100
Study: 12574218

Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet; 40% carbohydrate and 30% protein
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low Protein (LP) diet; 55% carbohydrate and 15% protein
Number of subjects: 28
Study: 10533826

Group type: EXPERIMENTAL
Intervention: RBCs stored for 6 weeks at 4 degrees C
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RBCs stored for 5 weeks at 4 degrees C except for 24 hours at 25 degrees C on Day 14
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RBCs stored for 5 weeks at 4 degrees C except for 24 hours at 25 degrees C on Day 28
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RBCs stored in AS-5 and allowed to warm to 25 degrees C for 24 hours
Number of subjects: 11
Study: 8704534

Group type: EXPERIMENTAL
Intervention: Troponin T positive group
Number of subjects: 460

Group type: COMPARATOR
Intervention: Troponin T negative group
Number of subjects: 460
Study: 1922801

Group type: EXPERIMENTAL
Intervention: Slow-release bromocriptine (14.2 +/- 0.7 mg/d, taken twice a day)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Standard bromocriptine (13.5 +/- 0.7 mg/d, taken three times a day)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Slow-release bromocriptine
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Slow-release bromocriptine and Standard bromocriptine
Number of subjects: 243
Study: 6297068

Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) + Detorubicin (120 mg/m2, IV every three weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) alone (250 mg/m2, IV, over 4 days every three weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) + Detorubicin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) alone
Number of subjects: 51
Study: 31964380

Group type: EXPERIMENTAL
Intervention: AL + day 1 primaquine (0.75 mg/kg)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: AL + day 3 primaquine (0.75 mg/kg)
Number of subjects: 111

Group type: COMPARATOR
Intervention: AL only
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: AL only and AL + day 1 primaquine
Number of subjects: 111
Study: 31323765

Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 44
Study: 28392264

Group type: COMPARATOR
Intervention: BodyPump (n=25)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Individual resistance training with a personal trainer (n=25)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Non-supervised individual resistance training (n=21)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Non-exercising control group (n=21)
Number of subjects: 92
Study: 26551184

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 162

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 162
Study: 22924758

Group type: EXPERIMENTAL
Intervention: Structured balance and agility exercises in addition to normal physical training
Number of subjects: 779